Evaluating high-dose rivastigmine patch in severe alzheimer’s disease: Analyses with concomitant memantine usage as a factor

Current Alzheimer Research

Volumn 12, Issue 1, 2015, Pages 53-60

  Grossberg, George T ^a   Farlow, Martin R ^b   Meng, Xiangyi ^c   Velting, Drew M ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACTION study; High dose; Memantine; Rivastigmine; Severe Alzheimer s disease; Transdermal patch

Indexed keywords

MEMANTINE; RIVASTIGMINE; DOPAMINE AGENTS; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES;

AGED; ALZHEIMER DISEASE; ANXIETY DISORDER; APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TRANSDERMAL PATCH; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CLINICAL TRIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGY; QUALITY OF LIFE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMANTINE; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84921833020     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666141218122835     Document Type: Article

References (26)

1. Rivastigmine (Exelon®) US Prescribing Information 2006; Available from: http://www.accessdata.fda.gov/drugsatfda_ docs/label/2006/020823s016,021025s008lbl.pdf (Accessed 24th October 2014).
2. Rivastigmine patch (Exelon Patch®) US Prescribing Information. 2009. Revised 2012 and 2013; Available from: http://www.pharma.us.novartis.com/ product/pi/pdf/exelonpatch.pdf (Accessed 24th October 2014).
3. Donepezil (Aricept®) US Prescribing Information. 2010; Available from: http://www.aricept.com/docs/pdf/aricept_PI.pdf (Accessed 24th October 2014).
4. Galantamine (Razadyne ER® and Razadyne®) US Prescribing Information. 2005; Available from: http://www.razadyneer.com/ sites/default/files/shared/pi/razadyne_er.pdf#zoom=100 (Accessed 24th October 2014).
5. Memantine (NAMENDA®) US Prescribing Information. 2011; Available from: http://www.frx.com/pi/namenda_pi.pdf (Accessed 24th October 2014).
6. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open 2(3): pii: e000917 (2012).
7. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291(3): 317-324 (2004).
8. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, doubleblind, placebo-controlled trial. Curr Alzheimer Res 5(1): 83-89 (2008).
9. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimer's Res Ther 5(1): 6 (2013).
10. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366(10): 893-903 (2012).
11. Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord 33(2-3): 164-173 (2012).
12. Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin 26(10): 2441-2447 (2010).
13. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther 19(10): 745-752 (2013).
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944 (1984).
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-198 (1975).
16. Saxton J, McGonigle-Gibson K, Swihart A, Miller M, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess 2: 298-303 (1990).
17. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(2): S33-39 (1997).
18. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41(10): 719-739 (2002).
19. Bailey JA, Lahiri DK. A novel effect of rivastigmine on presynaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112(4): 843-853 (2010).
20. Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Abeta and increases sAPPalpha levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6(7): e21954 (2011).
21. Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2: 68-72 (2000).
22. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281(15): 1401-1406 (1999).
23. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22(5): 456-467 (2007).
24. Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 27(7): 1375-1383 (2011).
25. Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin 26(2): 263-269 (2010).
26. Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician 83(12): 1403-1412 (2011). Erratum in Am Fam Physician 90(4): 209 (2014)